RLD2004

Hanmi Pharmaceutical Company Limited · Phase 2 active Small molecule

RLD2004, developed by Hanmi Pharmaceutical, is a novel drug currently in Phase 2 clinical trials for essential hypertension. The drug has not yet received FDA approval and has no commercial revenue. Safety data and detailed mechanism of action are not available.

At a glance

Generic name	RLD2004
Sponsor	Hanmi Pharmaceutical Company Limited
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RLD2004 CI brief — competitive landscape report
RLD2004 updates RSS · CI watch RSS
Hanmi Pharmaceutical Company Limited portfolio CI